Axa decreased its position in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 2.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,120 shares of the biopharmaceutical company’s stock after selling 1,344 shares during the period. Axa’s holdings in SAGE Therapeutics were worth $7,432,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of SAGE Therapeutics by 23.6% in the fourth quarter. Geode Capital Management LLC now owns 380,896 shares of the biopharmaceutical company’s stock valued at $62,737,000 after purchasing an additional 72,790 shares in the last quarter. Amalgamated Bank increased its holdings in shares of SAGE Therapeutics by 16.9% in the fourth quarter. Amalgamated Bank now owns 5,147 shares of the biopharmaceutical company’s stock valued at $848,000 after purchasing an additional 744 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at approximately $3,277,000. Carillon Tower Advisers Inc. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at approximately $74,300,000. Finally, Brown Advisory Inc. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at approximately $517,000. 96.29% of the stock is owned by institutional investors.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. JPMorgan Chase & Co. reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, January 10th. Stifel Nicolaus reissued a “buy” rating and issued a $198.00 price target on shares of SAGE Therapeutics in a report on Friday, December 8th. Cowen reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Monday, December 11th. Finally, Morgan Stanley began coverage on shares of SAGE Therapeutics in a research note on Monday, February 26th. They issued an “overweight” rating and a $225.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the stock. SAGE Therapeutics has a consensus rating of “Buy” and a consensus price target of $176.47.
SAGE Therapeutics Inc (SAGE) opened at $173.91 on Wednesday. SAGE Therapeutics Inc has a 52 week low of $59.57 and a 52 week high of $195.97. The stock has a market cap of $8,000.00, a P/E ratio of -24.53 and a beta of 3.07.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.23. During the same quarter in the prior year, the firm earned ($1.50) earnings per share. equities analysts predict that SAGE Therapeutics Inc will post -8.2 EPS for the current fiscal year.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.